SPOREGEN LIMITED

Their core work

SPOREGEN LIMITED is a London-based biotechnology SME specialising in immunology, with a particular focus on mucosal immune responses and their application in vaccine and disease prevention research. Their work sits at the intersection of human and animal health: they contributed to research on novel tuberculosis vaccine strategies targeting mucosal immunity in humans, and separately to improving livestock health and productivity through immune modulation. The company name likely reflects a spore-based biological platform — a technology used in oral and mucosal vaccine delivery — which would explain their consistent presence across both human and animal immune response projects. As a small private company, they appear to function as a specialist scientific contributor within larger research consortia rather than as an integrator or coordinator.

What they specialise in

How they've shifted over time

SPOREGEN's two H2020 projects ran concurrently from 2015 to 2019, making it impossible to identify a temporal shift in focus — both efforts were active at the same time, not sequential. What this simultaneous dual engagement does reveal is a deliberate strategy of operating across human and animal immunology in parallel, rather than a linear evolution from one domain to another. Beyond 2019, there are no further H2020 projects in the data, so whether the organisation deepened, pivoted, or scaled back its research activity cannot be determined from this dataset alone.

With both projects running in the same 2015–2019 window and no H2020 activity after that, the direction of travel is unclear — a potential partner should verify whether SPOREGEN remains active in research collaborations post-2019 before assuming continued availability.

How they like to work

SPOREGEN participates exclusively as a consortium partner and has never led an H2020 project, which is consistent with a small specialist firm that contributes targeted scientific expertise rather than managing large research programmes. Despite having only two projects, they accumulated 34 unique partners across 15 countries, suggesting they joined sizeable international consortia rather than small bilateral arrangements. This profile — deep specialist in large multi-partner RIA consortia — means they are most valuable to consortium builders who need a focused immunology or vaccine biology contributor, not a coordination hub.

SPOREGEN has built a surprisingly broad network for a two-project organisation: 34 unique consortium partners spread across 15 countries, reflecting the international scale typical of RIA consortia in health and food research. No geographic concentration is visible from the available data.

What sets them apart

SPOREGEN occupies an unusual niche as a private UK SME with demonstrable experience in both human infectious disease immunology and livestock immune health — a combination that positions them naturally within One Health research frameworks where human, animal, and environmental health intersect. Their involvement in tuberculosis mucosal immunity research alongside animal production health suggests access to biological platforms or expertise relevant to oral, mucosal, or spore-based delivery systems, which remain an active area of interest for next-generation vaccines. For a consortium looking for a lean, specialist partner with credibility on both sides of the human–animal health divide, SPOREGEN represents a rare fit.

Highlights from their portfolio

• EMI-TB
  The larger of the two projects (EUR 436,047), focused on tuberculosis — one of the world's leading infectious disease killers — specifically targeting mucosal immune pathways, which remain a key frontier in TB vaccine development.
• SAPHIR
  Bridges food security and animal health by targeting immune response mechanisms in livestock, reflecting SPOREGEN's capacity to translate immunology expertise into agricultural productivity contexts.